Sensus Healthcare, Inc. Q1 2026 Earnings Recap

Sensus Healthcare’s shares plunged 24.7% after earnings, driven by cautious outlook signals and execution risks around the transition to the new CPT code environment, despite management’s positive framing of increasing adoption and pipeline development.

Key Takeaways

• The company highlighted a pivotal transition to new CPT codes for superficial radiotherapy and is focused on educating the market and driving adoption.
• Reported shipments included 14 SRT systems with progress in diversifying the customer base and reducing historical customer concentration, matching Q4 levels.
• Treatment volumes increased 8% year-over-year, supported by 18 active FDA sites and 9 pending activations, fueling recurring revenue streams estimated at ~10% of total revenue.
• Launched new financial services and SensusLink software to drive recurring revenue, aiming to shift customer preferences from rental agreements to purchases.
• Despite these initiatives, investors reacted negatively, likely signaling disappointment in either the pace of execution, deceleration risks, or concerns over profitability and sustainable margin improvement amid ongoing market uncertainty.